WHO Not Finished Yet: Now is the Time to End Childhood Tuberculosis [GUEST ESSAY] Newsletter Edition #201 [The Curated Primer - Featured in GHF] By Priti Patnaik / 17 Nov 2023
Access to Medicines A Little Fairer is Not Good Enough: Why ABS Will NOT Ensure Equity [GUEST ESSAY] Newsletter Edition #55 [Treaty Talks] By Priti Patnaik / 15 Nov 2023
Negotiating Text "Pandemic Treaty Talks Hobbled by Inefficient Process": Negotiators. Countries Struggle Charting a Path While Also Debating Provisions Newsletter Edition #54 [Treaty Talks] By Priti Patnaik / 10 Nov 2023
Negotiating Text Palestine & "Unbalanced Text" Dominate Concerns of Developing Countries, Developed Countries Bristle at IP & Financing [Country Statements: INB7] Newsletter Edition #53 [Treaty Talks] By Priti Patnaik / 9 Nov 2023
COVID-19 The Pandemic Accord Needs Clear Commitments on Adequate & Fair Financing for Prevention Preparedness and Response [GUEST ESSAY] Newsletter Edition #52 [Treaty Talks] By Priti Patnaik / 8 Nov 2023
INB May 2024 Deadline Conditional on Meeting Demands on Equity: 29 Member States of the Equity Group Newsletter Edition #51 [Treaty Talks - The Files Brief] By Priti Patnaik / 3 Nov 2023
access and benefit sharing Squaring The Circle On Equity in a Pathogen Access And Benefit Sharing System [Guest Essay] Newsletter Edition #50 [Treaty Talks] By Priti Patnaik / 1 Nov 2023
Vaccines “There is really no moral, legal, justifiable ground for this level of secrecy, you need to bring the light in’’: Fatima Hassan on the Fight for Transparency of COVID-19 Vaccine Contracts Newsletter Edition #49 [Treaty Talks - The Files Interview] By Priti Patnaik / 25 Oct 2023
Negotiating Text Draft Pandemic Agreement Text Does Not Bite the Bullet, Suggests Subsequent Protocols To Defer Commitments on Key Issues Newsletter Edition #48 [Treaty Talks] By Priti Patnaik / 19 Oct 2023
COVID-19 The Tightrope of Scientific Inquiry, State Sovereignty and Global Health Governance in Tracing COVID-19 Origins Newsletter Edition #47 [Treaty Talks - IHR] By Priti Patnaik / 12 Oct 2023
INB Push to Prioritize Prevention Over Response in the Negotiations to Amend the IHR, Developing Countries Dig Their Heels To Preserve Equity Proposals Newsletter Edition #46 [Treaty Talks - IHR] By Priti Patnaik / 10 Oct 2023
Pricing Johnson & Johnson’s Patenting & Pricing Strategy for TB Medicine Bedaquiline: A Cautionary Tale for New TB Medicines [GUEST ESSAY] Newsletter Edition #200 [The Curated Primer] By Priti Patnaik / 6 Oct 2023
![Not Finished Yet: Now is the Time to End Childhood Tuberculosis [GUEST ESSAY]](https://storage.ghost.io/c/3e/27/3e275aa8-3271-4edb-ac7b-04dcacf8a053/content/images/size/w30/substack-post-media-s3-amazonaws-com/public/images/1cfa21a8-607d-4b8f-82ea-114e56883691_8192x6161.jpg)
![A Little Fairer is Not Good Enough: Why ABS Will NOT Ensure Equity [GUEST ESSAY]](https://storage.ghost.io/c/3e/27/3e275aa8-3271-4edb-ac7b-04dcacf8a053/content/images/size/w30/substack-post-media-s3-amazonaws-com/public/images/c194a843-3625-4993-b6de-3b4b4e4c5f51_5616x3744.jpg)
![Not Finished Yet: Now is the Time to End Childhood Tuberculosis [GUEST ESSAY]](https://storage.ghost.io/c/3e/27/3e275aa8-3271-4edb-ac7b-04dcacf8a053/content/images/size/w960/format/webp/substack-post-media-s3-amazonaws-com/public/images/1cfa21a8-607d-4b8f-82ea-114e56883691_8192x6161.jpg)
![A Little Fairer is Not Good Enough: Why ABS Will NOT Ensure Equity [GUEST ESSAY]](https://storage.ghost.io/c/3e/27/3e275aa8-3271-4edb-ac7b-04dcacf8a053/content/images/size/w960/format/webp/substack-post-media-s3-amazonaws-com/public/images/c194a843-3625-4993-b6de-3b4b4e4c5f51_5616x3744.jpg)
![Palestine & "Unbalanced Text" Dominate Concerns of Developing Countries, Developed Countries Bristle at IP & Financing [Country Statements: INB7]](https://storage.ghost.io/c/3e/27/3e275aa8-3271-4edb-ac7b-04dcacf8a053/content/images/size/w960/format/webp/substack-post-media-s3-amazonaws-com/public/images/5c547193-c40a-450b-a496-48c729b692f4_4000x6000.jpg)
![The Pandemic Accord Needs Clear Commitments on Adequate & Fair Financing for Prevention Preparedness and Response [GUEST ESSAY]](https://storage.ghost.io/c/3e/27/3e275aa8-3271-4edb-ac7b-04dcacf8a053/content/images/size/w960/format/webp/substack-post-media-s3-amazonaws-com/public/images/dc6bb3c1-762c-409b-b4ef-c5f8ff1b3db5_3766x2489.jpg)
![Squaring The Circle On Equity in a Pathogen Access And Benefit Sharing System [Guest Essay]](https://storage.ghost.io/c/3e/27/3e275aa8-3271-4edb-ac7b-04dcacf8a053/content/images/size/w960/format/webp/substack-post-media-s3-amazonaws-com/public/images/8087dada-2711-4b3c-9ec9-ab5c7d4f2dec_4000x2667.jpg)
![Johnson & Johnson’s Patenting & Pricing Strategy for TB Medicine Bedaquiline: A Cautionary Tale for New TB Medicines [GUEST ESSAY]](https://storage.ghost.io/c/3e/27/3e275aa8-3271-4edb-ac7b-04dcacf8a053/content/images/size/w960/format/webp/substack-post-media-s3-amazonaws-com/public/images/f36f3802-bd56-4ad0-bc72-fe2fe0929e3d_4032x3024.jpg)